Assessing TP53 status in human tumours to evaluate clinical outcome.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 11902578.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
TP53 is probably the most extensively studied tumour-suppressor gene, and patients with TP53 mutations are known to have a poor outcome. However, inconsistencies in the analysis of TP53 status, and failure to realize that different mutations behave in different ways, prevent us from effectively applying our vast knowledge of this protein in clinical practice. What simple steps can be taken to ensure that patients benefit from our understanding of TP53?
Medical subject headings
- Genes, p53
- Membrane Proteins
- Neoplasms